|
See related Pariet film-coated tab information |
|
|
|
Manufacturer |
Eisai |
|
Distributor |
DKSH |
|
Contents |
Rabeprazole Na |
|
Indications |
Active duodenal, active benign gastric & anastomotic ulcers, erosive or ulcerative GERD, GERD maintenance, symptomatic GERD, Zollinger-Ellison syndrome & other pathological hypersecretory conditions. In combination w/ appropriate antibacterial therapeutic regimens for eradication of H. pylori in patients w/ PUD.
Click to view Pariet detailed prescribing infomation |
|
Dosage |
Adult & elderly Active duodenal, active benign gastric & anastomotic ulcers, erosive or ulcerative GERD & GERD maintenance 10-20 mg once daily. Symptomatic GERD 10 mg once daily. When symptom has resolved, use as on-demand regimen for subsequent symptom control. Short-term (up to 8 wk) treatment of GERD Adolescent ≥12 yr 20 mg once daily up to 8 wk. Zollinger-Ellison syndrome Individualized dosage. Initially 60 mg daily. Doses up to 100 mg daily or 60 mg bid have been used. Eradication of H. pylori Pariet 20 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid for 7 days.
Click to view Pariet detailed prescribing infomation |
|
Overdosage |
View Pariet overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not chew/crush.). |
|
Contraindications |
[Click for Pariet detailed prescribing infomation] |
|
Special Precautions |
Exclude gastric or esophageal malignancy. Long-term treatment. Severe hepatic dysfunction. Pregnancy & lactation. Childn.
Click to view Pariet detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, diarrhea, abdominal pain, asthenia, flatulence, rash & dry mouth.
View ADR Monitoring Form |
|
Drug Interactions |
Decreases ketoconazole or itraconazole plasma levels.
View more drug interactions with Pariet |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Pariet storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Pariet description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Pariet mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Special Feature |
Researched & developed in Japan by Eisai Co., LtdUS FDA Approved |
|
